Philana Ling Lin, MD, MSc

  • Associate Professor of Pediatrics
  • Director, Pediatric Infectious Diseases Fellowship, UPMC Children's Hospital of Pittsburgh

Lin completed her pediatric residency at the University of Chicago Children's Hospital and pediatric infectious disease fellowship at the Children's Hospital of Pittsburgh. She is currently an Associate Professor and accomplished physician scientist. The focus of her research is on the pathogenesis of Tuberculosis (TB) with a special interest in HIV-TB confection. Other interests include TB vaccines and the epidemiology of invasive pneumococcal disease.

Professional and Scientific Society Memberships

  • American Academy of Pediatrics (AAP), 2000-Present 
  • Pediatric Infectious Diseases Society (PIDS), 2000-Present
  • Infectious Diseases Society of America (IDSA), 2000-Present
  • Society of Pediatric Research (SPR), 2009-Present
  • American Association of Immunology (AAI), 2012-Present
  • American Society of Microbiology (ASM), 2013-Present

Education & Training

  • BS, Youngstown State University, 1992
  • MS, Northeastern Ohio Universities College of Medicine, 1996
  • Internship, University of Chicago Affiliate-MacNeal Hospital, 1996-1997
  • Residency in Pediatrics, University of Chicago Comer Children's Hospital, 1997-2000
  • Fellowship in Pediatrics, UPMC Children's Hospital of Pittsburgh, 2000-2003
  • MS, Clinical Research University of Pittsburgh Clinical School of Medicine, 2001-2004

Selected Publications

Academic and Research Interests

R56 AI139053, Contribution of CD8 T cells In controlling TB, (PI, 10% effort), 2018-2019, NIH 

R21- AI127173, Antibodies associated with Collaborator protection against TB in non-human primates, (PI, 5% effort), 2017-2019, NIH 

R01-AI134195, Influence of SIV replication on TB progression & Immunity, (PI, 15% effort), 2017-2021, NIH 

R01 AI123093, Predicting Protective T cell Responses in TB using Systems Biology Approach, (PI, 5% effort), 2016-2021, NIH 

Blood signature of reactivation Tuberculosis risk, (PI, 5% effort), 2017-2020, PA CURE  

R21-AI127066, Host & Pathogen Diversity in Mtb & SIV  infection, (PI, 10% effort), 2016-2018, NIH 

R01-AI111871HIV-TB, Co-infection: Tracking TB emergence after asymptomatic infection, (PI, 15% effort), 2014-2019, NIH 

R01-AI114674, Consequences of Reinfection with M. tuberculosis, (PI,10% effort), 2015-2019, NIH 

R01-AI118195PET, Probes Targeting Immune Cells for Imaging TB, (PI, 5% effort), 2015-2020, NIH 

NoneImmune Signatures of Differential NHP granuloma States, (PI, 10% effort), 2016-2018, Harvard SPH